Hengrui Pharmaceuticals Shares Jump Over 3% in Sharp Rally

A straight-line intraday move of this size in a large-cap pharmaceutical name usually points to a single catalyst rather than broad sector flow, so the absence of an identified cause is itself the story. For RWA and crypto-market readers, the relevant thread is that China's listed healthcare complex remains a source of sharp, headline-driven repricing that can spill into tokenized equity and biotech-linked products, even when the underlying driver is unclear. Whether a concrete explanation surfaces, or the move fades without one, is the open question.